Recombinant Rat NRN1 Protein，His

N-Ras is a member of the Ras family of proteins, which are integral to cell signaling pathways that control cell growth, differentiation, and survival. Dysfunction or mutations in Ras proteins, particularly N-Ras, are implicated in various cancers, including melanoma, leukemia, and thyroid cancers. The study of recombinant N-Ras (NRN1) proteins has gained significant attention in recent years due to their potential as therapeutic targets and the need for better understanding of their structure-function relationships. Researchers are developing recombinant NRN1 proteins to investigate the biochemical mechanisms underlying Ras signaling, explore its role in tumorigenesis, and identify potential intervention strategies. Additionally, studying these recombinant proteins allows for the examination of the effects of specific mutations in Ras and the interaction with downstream effectors. Understanding these processes can lead to the development of novel drugs that can disrupt aberrant Ras signaling pathways. The advancement of techniques such as CRISPR/Cas9 and structural biology has also facilitated the exploration of NRN1, leading to more insights into its interactions and the identification of small molecules that can inhibit its activity. This research is crucial for developing targeted therapies that could improve outcomes for cancer patients with Ras-driven malignancies, ultimately contributing to the field of personalized medicine.